Increasing the human chorionic gonadotrophin cut-off to ≤1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy
Open Access
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- First-line chemotherapy in low-risk gestational trophoblastic neoplasiaCochrane Database of Systematic Reviews, 2016
- Optimal management of low-risk gestational trophoblastic neoplasiaExpert Review of Anticancer Therapy, 2015
- Effects of Single-Agent and Combination Chemotherapy for Gestational Trophoblastic Tumors on Risks of Second Malignancy and Early MenopauseJournal of Clinical Oncology, 2015
- Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- Prognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasiaGynecologic Oncology, 2013
- Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009British Journal of Cancer, 2012
- Gestational trophoblastic diseaseThe Lancet, 2010
- Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational studyThe Lancet, 2009
- Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE)Annals of Oncology, 2008
- Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989BJOG: An International Journal of Obstetrics & Gynaecology, 1991